Drug Trial Radar · NCT04045665
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3,200
Planned (sponsor's estimate)
Start
Dec 13, 2019
Primary completion
Aug 31, 2026
Study completion Aug 31, 2026
Sponsor
- Lead sponsor
- Icahn School of Medicine at Mount SinaiAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI); Vanderbilt University Medical Center
- First posted
- Aug 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their baseline risk profile and their treatment strategy in terms of anticoagulants or antiplatelets received. These patients will also be asked to fill out a brief decliner survey.
Conditions
- Atrial Fibrillation
- Stroke
- Bleeding
Interventions
Antiplatelet-only strategyDrug
Aspirin 75-325 mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)
Oral Anticoagulant plus background antiplatelet therapyDrug
OAC with vitamin K antagonist (VKA) with international normalized ratio (INR) target 2-3 or any approved direct oral anticoagulant OR apixaban, rivaroxaban, edoxaban or dabigatran) in addition to background antiplatelet therapy with aspirin 75-325mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite of death, ischemic stroke, TIA, MI, systemic arterial thromboembolism or venous thromboembolism (DVT and/or PE)Time frame: up to 180 days after randomization
- Any BARC type 3 or 5Time frame: 90 days after randomization
Locations
106 sites in 5 countries. Site status is shown where the registry gives one.
CHI St. Vincent, Arkansas
Little Rock, Arkansas · Recruiting
University of Southern California
Los Angeles, California · Recruiting
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
Stanford University
Stanford, California · Recruiting
Medical Center of Aurora
Aurora, Colorado · Active not recruiting
Western Connecticut Hospital Systems
Danbury, Connecticut · Active not recruiting
Yale Medicine
New Haven, Connecticut · Recruiting
MedStar Washington Hospital Center
Washington D.C., District of Columbia · Recruiting
Emory University
Atlanta, Georgia · Recruiting
Piedmont Healthcare Inc.
Atlanta, Georgia · Recruiting
Lutheran Medical Center
Fort Wayne, Indiana · Active not recruiting
Indiana University
Indianapolis, Indiana · Active not recruiting
Ascension St. Vincent
Indianapolis, Indiana · Active not recruiting
Ochsner Clinic
New Orleans, Louisiana · Recruiting
Maine Medical Center
Portland, Maine · Recruiting
University of Maryland
Baltimore, Maryland · Recruiting
Johns Hopkins
Baltimore, Maryland · Recruiting
Suburban Hospital
Bethesda, Maryland · Active not recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Brigham and Women's Hospital
Boston, Massachusetts · Recruiting
Boston Medical Center
Boston, Massachusetts · Active not recruiting
Baystate Health
Springfield, Massachusetts · Active not recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Mid America Health Institute
Kansas City, Missouri · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire · Recruiting
Jersey Shore University Medical Center
Neptune City, New Jersey · Recruiting
Northwell Health System
Great Neck, New York · Recruiting
The Mount Sinai Hospital
New York, New York · Withdrawn
Columbia University Medical Center
New York, New York · Recruiting
Montefiore Medical Center
The Bronx, New York · Recruiting
Duke University
Durham, North Carolina · Recruiting
East Carolina University
Greenville, North Carolina · Recruiting
WakeMed
Raleigh, North Carolina · Withdrawn
Cleveland Clinic Foundation
Cleveland, Ohio · Recruiting
Ohio State University Medical Center
Columbus, Ohio · Active not recruiting
Ascension St. John
Tulsa, Oklahoma · Active not recruiting
University of Pittsburgh Medical Center
Hermitage, Pennsylvania · Withdrawn
University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
Showing 40 of 106 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.